What is he best known for?
The fields of study he is best known for:
- Antibody
- Immune system
- Cancer
Martin J. Glennie mainly investigates Monoclonal antibody, Antibody, Immunology, CD20 and Antigen.
His studies in Monoclonal antibody integrate themes in fields like Biochemistry, Intracellular, Cell biology, Molecular biology and Cytotoxicity.
Martin J. Glennie has included themes like Epitope, Epitope mapping and CD8 in his Molecular biology study.
His Antibody study combines topics from a wide range of disciplines, such as CD28 and Cytotoxic T cell.
His Immunology study often links to related topics such as Cancer.
His CD20 research integrates issues from Monoclonal, Virology, B cell, Rituximab and Chronic lymphocytic leukemia.
His most cited work include:
- Guidelines for the welfare and use of animals in cancer research (937 citations)
- Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas (593 citations)
- The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 (548 citations)
What are the main themes of his work throughout his whole career to date?
Martin J. Glennie mostly deals with Antibody, Monoclonal antibody, Immunology, Antigen and Molecular biology.
His research in Antibody intersects with topics in Receptor and Effector, Cell biology.
His research integrates issues of Cancer research, Immunotherapy, Epitope, In vivo and CD20 in his study of Monoclonal antibody.
His Cancer research study combines topics in areas such as Cancer and CD19.
Martin J. Glennie works mostly in the field of Immunology, limiting it down to topics relating to Cytotoxic T cell and, in certain cases, CD8 and T cell, as a part of the same area of interest.
In his study, Antigenic Modulation is inextricably linked to Idiotype, which falls within the broad field of Molecular biology.
He most often published in these fields:
- Antibody (52.86%)
- Monoclonal antibody (52.86%)
- Immunology (52.86%)
What were the highlights of his more recent work (between 2015-2020)?
- Monoclonal antibody (52.86%)
- Antibody (52.86%)
- Immunology (52.86%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Monoclonal antibody, Antibody, Immunology, Receptor and Cancer research.
He has researched Monoclonal antibody in several fields, including Cytokine, Myeloid, CD8, Epitope and Immunotherapy.
His research in Antibody intersects with topics in Cell biology, Effector and Angiogenesis.
His Cell biology study integrates concerns from other disciplines, such as Molecular biology, Transfection and Cell membrane.
His research ties Cytotoxicity and Immunology together.
His studies deal with areas such as T cell, Immune system, Cell and Cancer as well as Cancer research.
Between 2015 and 2020, his most popular works were:
- Influence of immunoglobulin isotype on therapeutic antibody function (69 citations)
- Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. (53 citations)
- Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. (51 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Antibody
- Cancer
Martin J. Glennie spends much of his time researching Monoclonal antibody, Antibody, Immunology, Cell biology and Cytotoxic T cell.
His biological study focuses on Isotype.
Martin J. Glennie is interested in Antibody variable region, which is a field of Antibody.
His study connects Receptor and Immunology.
Martin J. Glennie combines subjects such as Immune system, CD8 and Major histocompatibility complex with his study of Cytotoxic T cell.
His Immune system research is multidisciplinary, incorporating elements of Antigen and CD40.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
